GLP-1 Drugs and the Immune System: New Research on Autoimmune Disease
As GLP-1 medications become increasingly common, researchers are looking beyond their effects on blood sugar and weight to better understand how they influence the immune system. While previous studies suggest these medications may reduce inflammation, their effects on autoimmune disease remain uncertain.
On October 21, 2026, the La Jolla Institute for Immunology (LJI) announced a new study led by Professor Alessandro Sette, Dr.Biol.Sci., investigating whether GLP-1 medications alter adaptive immunity, the part of the immune system responsible for recognizing specific threats and developing immune memory.
Researchers will collect blood samples before individuals begin GLP-1 treatment and throughout the following months, examining whether the medications change T-cell responses to targets associated with infections, vaccines, and neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
These questions are particularly relevant to autoimmune research, where the immune system mistakenly targets the body’s own tissues. Understanding whether GLP-1 medications influence how T cells recognize specific targets could provide new insight into their broader effects on immune function.
Meanwhile, research into GLP-1 medications and autoimmune disease continues to produce mixed findings.
Some observational studies suggest benefits for people with inflammatory bowel disease, including fewer hospitalizations and complications, while other studies have identified differing associations with the development of certain autoimmune conditions. Importantly, reducing inflammation does not necessarily mean a medication directly treats the underlying autoimmune disease.
LJI’s study is still in its early stages and is not intended to establish GLP-1 medications as treatments for immune-related conditions. However, its findings could help researchers distinguish direct effects on immune responses from improvements associated with weight loss and metabolic health.
For a closer look at the existing evidence, potential risks, and considerations for people living with autoimmune disease, read GAI’s GLP-1 Receptor Agonists and Autoimmune Diseases by Jennifer Tsang, PhD.
References
- Hernandez, R. (2026, October 21). Could GLP-1 drugs change how the immune system responds to disease? La Jolla Institute for Immunology.
- Swearingen, K. (2026, October 20). Are GLP-1s safe for people with autoimmune disorders? What our experts say. Healthline.